Composite artificial liver supporting system and its usage

Abstract

The composite artificial liver supporting system incldues a blood and plasma displacing unit for eliminating toxic matter and harmful matter and one biological artificial liver unit. The displacing unit includes plasma separator for separating patient's plasma and exhausting separated plasma, healthy blood leading in device with pump, valve and pipeline, and thermostat device to maintain the blood and plasma displacing unit at body's temperature. The biological artificial liver unit bioreactor comprising culture device and matter exchanger, blood and plasma flow stabilizer, culture liquid stabilizer and thermostat. Its using method includes the steps of detoxicating patient's blood and plasma, cutlruing exogenous cell, and utilizing the exogenous cell for synthesis, metabolism and matter exchange.

Description

technical field [0001] The present invention relates to a compound artificial liver support system, more specifically, relates to a system that can replace the liver function of patients with acute liver failure (acute liver failure, ALF) in a long period of time, and support patients with severe liver failure Waiting for liver transplantation, or allowing patients with liver failure to gradually restore their own liver tissue and its regeneration and compensation functions, thereby improving the survival rate and survival time of ALF patients with a compound artificial liver support system. In addition, the present invention also relates to the use method of the above-mentioned composite artificial liver support system, which can greatly improve the therapeutic effect of the above-mentioned system. Background technique [0002] Acute liver failure is a common critical disease with a mortality rate as high as 70-90%. For this disease, the current treatment methods generally...

AI Technical Summary

Problems solved by technology

However, when there is a large amount of toxic substances or macromolecular substances that cannot pass through the semi-permeable membrane in the patient's blood / plasma, this device becomes ineffective, and the exogenous hepatocytes cultured in BALSS quickly lose their vitality , therefore, it is impossible to obtain a significant therapeutic effect in a short period of time, thus losing the opportunity to save the patient

[0011] And, more importantly, in the above-mentioned patent application, only enumerate some test data of the time and reaction effect of test animal liver cell survival in the bioreactor, do not enumerate the application of this device and method on the human body The actual clinical effect of the treatment of liver failure

Images